Diabetes Care

Assertio Holdings, Inc. Announces Leadership Transition

Retrieved on: 
Wednesday, January 3, 2024
Diabetes Care, Nutrition, Abbott Laboratories, Growth, Patient, History, Global marketing, Senior, Management

LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Dan Peisert is stepping down as the Company’s Chief Executive Officer. The Board has appointed Heather Mason, currently an independent director of the Company and Chair of its Nominating and Corporate Governance Committee, to serve as interim CEO as the Company conducts a search for a permanent chief executive.

Key Points: 
  • LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced today that Dan Peisert is stepping down as the Company’s Chief Executive Officer.
  • The Board has appointed Heather Mason, currently an independent director of the Company and Chair of its Nominating and Corporate Governance Committee, to serve as interim CEO as the Company conducts a search for a permanent chief executive.
  • “I am committed to Assertio and its employees and stakeholders, and its future success,” Ms. Mason said.
  • “I will work to ensure that we are best positioned to maximize the opportunities in front of us, and to ensure a smooth leadership transition as we bring in a CEO to lead the Company into the next phase of our business.”

Know Labs Expands Board of Directors

Retrieved on: 
Wednesday, November 8, 2023
Science, Research, Hardware, General Health, Health, Consumer Electronics, Health Technology, Technology, Knowledge, American Diabetes Association, FDA, Patent, NYSE, Know Labs, Intellectual Ventures, Eli Lilly, Diabetes, IAM, Commercial, Head, Algorithm, Ellingson, IP, IBM, Diagnosis, Diabetes Care, Management, Pharmaceutical industry, Chemistry

Tim Londergan is the founder and CEO of Tangibly, Inc., developer of the globe’s pre-eminent trade secret management platform. Trade secrets are a key component of an IP asset base and include the company’s proprietary algorithms. Londergan has a Ph.D. in Chemistry and experience as a CEO and COO of technology companies, including Lumera, Wavefront Venture Labs and Operem. He spent several years as Head of Commercial Development at Intellectual Ventures--a six-billion-dollar global intellectual property fund. In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs’ IP portfolio. Recently, Londergan was named IAM 300 World’s Leading IP Strategist 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company’s Board of Directors.
  • Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs.
  • In that role he managed a project between Intellectual Ventures and Know Labs to enhance Know Labs’ IP portfolio.
  • We are thrilled to have John Cronin, Larry Ellingson and Tim Londergan join our Board of Directors.”
    For more information on Know Labs, visit www.knowlabs.co .

Prefilled Syringes Market Size & Share Analysis Report 2023 - Global Growth Trends & Forecasts to 2028 Featuring Key Players - BD & Co, Terumo, Gerresheimer, SCHOTT, & West Pharmaceutical Services - ResearchAndMarkets.com

Retrieved on: 
Friday, September 22, 2023
Infectious Diseases, COVID-19, Health, Pharmaceutical, Medical Supplies, Vaccine, Conditional sentence, Insulin, MDI, Prevalence, Diabetes, Vaccination, World Health Organization's response to the COVID-19 pandemic, Diabetes Care, IDF, International Diabetes Federation, Messenger, USD, Dickinson, COVID-19 vaccine, Medtronic, Patient, Novo Nordisk, Growth, NewCo, Ageing, NHS, FDA, SCHOTT, Safety, Glass, Rheumatoid arthritis, BD, Syringe, Pharmaceutical industry

The "Prefilled Syringes Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prefilled Syringes Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's offering.
  • Notable companies operating in the prefilled syringes market include Becton, Dickinson, and Company, Terumo Corporation, Gerresheimer AG, SCHOTT, West Pharmaceutical Services, Inc., and West Pharmaceutical Services, Inc., among others.
  • The global prefilled syringes market experienced a positive impact from the COVID-19 pandemic, primarily due to the potential use of prefilled syringes for COVID-19 vaccines.
  • This transition from vials to prefilled syringes was aimed at addressing the cost and complexity of vaccine administration.

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany

Retrieved on: 
Friday, September 1, 2023
Medical Supplies, Medical Devices, Health, Diabetes, Health Technology, General Health, CGM, Dexcom, Hypoglycemia, AID, Senior, Pharmaceutical industry in Switzerland, Tandem, G6, DXCM, Defensive aids system, Ecosystem, United, Glycated hemoglobin, LATAM, Pharmaceutical industry, Diabetes Care

Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” said Alex Moussa, Senior Vice President and General Manager, Dexcom EMEA & LATAM.

Key Points: 
  • Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” said Alex Moussa, Senior Vice President and General Manager, Dexcom EMEA & LATAM.
  • By adding another AID product to its CGM ecosystem, Dexcom has both strengthened its position as the world’s most connected CGM, with the Dexcom G6, and offered yet another AID choice to those living with type 1 diabetes in Germany.
  • “At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community.
  • To learn more about how Dexcom G6 offers the widest range of AID solutions for users and HCPs, visit Dexcom.com.

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

Retrieved on: 
Thursday, August 31, 2023
AWARD, The New England Journal of Medicine, Medical Affairs Bureau, Cell Metabolism, University, MOA, Therapy, Diabetes, T1D, Diabetes Care, STEP, Coronavirus Scientific Advisory Board, CMO, CDO, Eli Lilly, AML, Morris, Publication, Patient, DSM-IV codes, Cancer, Chief medical informatics officer, DURATION, Amylin Pharmaceuticals, Johnson & Johnson, Safety, Disease, Pharmaceutical industry, Endocrinology, Lancet, Pfizer, Osteopathic medicine in Canada

as Chief Medical Officer (CMO).

Key Points: 
  • as Chief Medical Officer (CMO).
  • Steve Morris, M.D., will transition to the new role of Chief Development Officer (CDO), where he will continue to lead clinical development of Biomea’s oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.
  • “The addition of Juan to the Biomea Leadership team is an important and exciting event for the company.
  • Our appointment of Juan to lead clinical development of BMF-219 in diabetes is a cornerstone of this strategy,” said Thomas Butler, CEO and Chairman of Biomea.

Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes

Retrieved on: 
Monday, July 10, 2023
Software, Research, General Health, Pharmaceutical, Technology, Infectious Diseases, Health Technology, Clinical Trials, Science, Biotechnology, FDA, Health, Diabetes, Psychology, Cognitive behavioral therapy, FRCP, De novo, DM, Overalls, FRCPE, Type 2 diabetes, PDT, Medicine, Better, Diabetes Technology Society, Food and Drug Administration Amendments Act of 2007, Digital health, HIV disease progression rates, Patient, Physician, Randomized controlled trial, Therapy, T2D, Food, Safety, Disease, Pharmaceutical industry, Diabetes Care

AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices.

Key Points: 
  • AspyreRx was reviewed through the FDA’s De Novo pathway and its authorization creates a new class of diabetes digital behavioral therapeutic devices.
  • “This De Novo authorization also provides a foundation for potential future growth opportunities.
  • AspyreRx is designed to address these barriers, leveraging technology to deliver an evidence-based therapeutic intervention to patients.
  • Investors and the general public may access a live webcast of the call by visiting https://edge.media-server.com/mmc/p/adggoags

Childhood Diabetes Screening Shown to Predict Future Diabetes-Related Complications

Retrieved on: 
Saturday, June 24, 2023
NIDDK, Ophthalmoscopy, Glycated hemoglobin, ACR, Aneurysm, Obesity, Diabetes, Kidney, Diabetes Care, Eye disease, Research, PG, Southwestern United States, Bangladesh Technical Education Board, Glycemia, Retinopathy, FAAP, Blood, Bleeding, Guideline, Risk, SAN, American Diabetes Association, American Indians, Albuminuria, Overweight, Digestive, Prediabetes, ADA, T2D, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Kidney disease, Syndrome, Dietary supplement, MD

SAN DIEGO, June 23, 2023 /PRNewswire/ -- New research from the National Institutes of Health (NIH) found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease (nephropathy) and eye disease (retinopathy). The findings were presented at the American Diabetes Association® (ADA) 2023 Scientific Sessions in San Diego, CA and were simultaneously published in the Diabetes Care journal.

Key Points: 
  • The findings were presented at the American Diabetes Association® (ADA) 2023 Scientific Sessions in San Diego, CA and were simultaneously published in the Diabetes Care journal.
  • This data comes at a time when the United States is experiencing a significant rise in obesity induced youth-onset type 2 diabetes (T2D).
  • As a result, ADA has recommended risk-based screening for prediabetes and/or diabetes in asymptomatic children with overweight or obesity by pediatric health care providers.
  • The study sought to evaluate the association of higher levels of glycemia during childhood with future microvascular complications in American Indian children – a population that is twice as likely to have diabetes than white individuals.

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System

Retrieved on: 
Wednesday, June 21, 2023
Apps, Applications, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biometrics, Health, CGM, Dexcom, Hypoglycemia, AID, Pharmaceutical industry in Switzerland, Diabetes Care, Tandem, G6, DXCM, Defensive aids system, Ecosystem, United, Glycated hemoglobin, Pharmaceutical industry

“For over a decade, Dexcom has been the sensor of choice for the development of AID systems.

Key Points: 
  • “For over a decade, Dexcom has been the sensor of choice for the development of AID systems.
  • Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide,” said Teri Lawver, Executive Vice President, Chief Commercial Officer at Dexcom.
  • By adding another AID product to its CGM ecosystem, Dexcom has both strengthened its position as the world’s most connected CGM, with the Dexcom G6, and offered yet another AID choice to those living with type 1 diabetes in the U.K.
    “At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community.
  • To learn more about how Dexcom G6 offers the widest range of AID solutions for users and HCPs, visit Dexcom.com .

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

Retrieved on: 
Tuesday, June 20, 2023
Faculty, KOL, San Diego Convention Center, Medical Affairs Bureau, University, Type 2 diabetes, Diabetes Care, Aqua, Diabetes, PT, CMO, Joslin Diabetes Center, Harvard Medical School, PIN, Patient, DSM-IV codes, Division, American Diabetes Association, Internal medicine, Cancer, Webcast, Johnson & Johnson, Principal, Phase, Safety, Conference, Osteopathic medicine in Canada, Pharmaceutical industry, Nightclub, Online shopping, Endocrinology, Medicine

Phase II consists of multiple ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.

Key Points: 
  • Phase II consists of multiple ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.
  • In March 2023, Biomea announced initial topline clinical data for the first two cohorts of patients with type 2 diabetes enrolled in the Phase II portion of the trial.
  • A link to the press release can be found here and a link to webcast can be found here .

GI Dynamics Announces an Update to the Worldwide Registry Data for 1,022 Patients Recently Published in Diabetes Care, the Journal of the American Diabetes Association

Retrieved on: 
Tuesday, April 4, 2023
Diabetes, Medical Devices, Hospitals, Health, Clinical Trials, Blood pressure, Macrovascular disease, Type 2 diabetes, Cholesterol, Cardiovascular disease, Risk, ABCD, Patient, Collection, T2D, Safety, Roux-en-Y anastomosis, City Hospital, Pharmaceutical industry, Glycated hemoglobin, Diabetes Care, Obesity

The article recently published in Diabetes Care, “Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide,” authored by Robert Ryder, M.D.

Key Points: 
  • The article recently published in Diabetes Care, “Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide,” authored by Robert Ryder, M.D.
  • of City Hospital, Birmingham, U.K, demonstrates treatment with EndoBarrier reduced microvascular and macrovascular risk factors that could reduce the complications of type 2 diabetes (T2D).
  • Over 3,000 patients have been treated with EndoBarrier worldwide, and in 2017 a secure, online registry was established by ABCD for the collection of safety and efficacy data for EndoBarrier treated patients worldwide.
  • The ABCD Worldwide EndoBarrier Registry, led by Dr. Ryder, collected data from 34 centers in ten countries.